SCHEMBL18705166

SCHEMBL18705166

CC(C)N1CC2(CN(C(=O)OC(C)(C)C)C2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HRH3 Q9Y5N1 1/20 0.40
HTT P42858 2/20 0.39
ATM Q13315 1/20 0.39
NR1H2 P55055 2/20 0.37
HPGD P15428 1/20 0.36
EPHX2 P34913 1/20 0.36
CYP11B2 P19099 1/20 0.36
GPR183 P32249 1/20 0.36
ACACB O00763 1/20 0.36
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
RORC P51449 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18705168 0.87 CYP11B2 (0.46) USP2SMN1; SMN2HRH3CYP11B2GPR183
SCHEMBL1394450 0.87 USP2 (0.52) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL12890163 0.85 HRH3 (0.43) USP2SMN1; SMN2HRH3HTTATM
SCHEMBL18375131 0.85 USP2 (0.46) USP2SMN1; SMN2HRH3HPGDCYP11B2
SCHEMBL18705163 0.85 CYP1A2 (0.46) USP2SMN1; SMN2HRH3HPGDCYP11B2
SCHEMBL18705162 0.83 SCD5 (0.46) USP2SMN1; SMN2HRH3CYP11B2GPR183
SCHEMBL30585418 0.83 USP2 (0.42) USP2SMN1; SMN2HTTATMNR1H2
SCHEMBL17260277 0.81 HRH3 (0.44) USP2SMN1; SMN2HRH3HTTHPGD
SCHEMBL3332085 0.81 USP2 (0.45) USP2SMN1; SMN2HRH3HPGDCYP11B2
SCHEMBL18374882 0.81 CYP11B2 (0.48) USP2SMN1; SMN2HRH3CYP11B2GPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067661-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2024-02-29 US disclosed
US-11780854-B2 Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2023-10-10 US disclosed
US-20230192723-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2023-06-22 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-07-17 US disclosed
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-07-05 US disclosed
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-06-28 US disclosed
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 USP2 4831/4885SMN1; SMN2 1161/4885HRH3 647/4885
US-20170096425-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3928/4885SMN1; SMN2 989/4885HRH3 1340/4885
US-20240067661-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF EGLN2, EGLN3, EGLN1 USP2 194/4885SMN1; SMN2 3950/4885HRH3 797/4885
US-20230192723-A1 PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF EGLN2, EGLN3, EGLN1 USP2 194/4885SMN1; SMN2 3950/4885HRH3 797/4885
US-20180186790-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3928/4885SMN1; SMN2 989/4885HRH3 1340/4885
US-20180186791-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3928/4885SMN1; SMN2 989/4885HRH3 1340/4885
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3928/4885SMN1; SMN2 989/4885HRH3 1340/4885
US-11780854-B2 Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof EGLN2, EGLN3, EGLN1 USP2 194/4885SMN1; SMN2 3950/4885HRH3 797/4885
US-10023570-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP2 3928/4885SMN1; SMN2 989/4885HRH3 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.